13F Holdings
中文EN

EVGN Evogene Ltd. IFRS Annual reports only

Agricultural Chemicals · Nasdaq · SEC CIK 1574565 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY87.0%
TTM net income YoY31.0%
TTM EPS YoY44.2%
Revenue 3-yr CAGR81.7%
Net income 3-yr CAGR—

Margins

Gross margin57.3%
Operating margin-337.2%
Net margin-295.6%
FCF margin-364.5%
EBITDA margin-312.4%

Returns

ROE-311.0%
ROA-36.2%
ROIC (approx.)—
Asset turnover0.12x

Leverage & solvency

Liabilities / assets62.8%
Debt / equity—
Current ratio1.15x
Interest coverage-5.60x

Cash quality & payout

Operating cash flow / net income1.20x
Accruals ratio7.1%
Payout ratio—
Capex / revenue11.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$3.85M$5.58M$2.98M$1.68M$930,000
Cost of revenue$4.09M$2.38M$1.49M$909,000$767,000
Gross profit-$241,000$3.20M$1.49M$766,000$163,000
R&D expense$7.99M$12.51M$16.20M$20.79M$21.12M
SG&A expense$4.29M$6.99M$5.38M$6.48M$7.25M
Operating income-$14.03M-$18.80M-$22.23M-$26.94M-$30.95M
Interest expense$1.93M$3.36M$928,000$3.33M$1.41M
Pretax income-$13.50M-$14.81M-$21.95M-$29.75M-$30.43M
Income tax$1,000$9,000$19,000$90,000$13,000
Net income-$8.48M-$16.48M-$23.88M-$26.64M-$27.79M
EBITDA-$12.89M-$17.42M-$20.93M-$25.43M-$29.65M
EPS (basic)1.08-2.90-5.20-6.44-0.69
EPS (diluted)1.08-2.90-5.20-6.44-0.69
Weighted avg. shares (diluted)7.87M5.70M4.59M4.14M40.43M
Balance sheet
Cash & equivalents$12.96M$15.30M$20.77M$28.98M$32.33M
Short-term investments—$10,000$10.29M$0$3.00M
Receivables$317,000$1.09M$357,000$348,000$281,000
Inventory$210,000$1.82M$76,000$566,000$92,000
Current assets$15.63M$21.59M$34.47M$37.75M$56.89M
PP&E, netmay include right-of-use assets (IFRS)$812,000$1.80M$2.46M$2.50M$2.07M
Intangibles$0$12.20M$13.17M$14.14M$15.21M
Total assets$20.05M$39.86M$51.10M$56.13M$76.30M
Current liabilities$3.44M$18.70M$6.94M$5.62M$6.88M
Total liabilities$8.07M$25.03M$22.42M$21.34M$12.88M
Shareholders' equity-$82,000-$1.45M$12.05M$27.93M$53.65M
Shares outstanding8.72M6.51M5.08M41.26M41.17M
Cash flow statement
Operating cash flow-$13.50M-$19.70M-$21.58M-$23.68M-$24.72M
Capital expenditure$135,000$626,000$577,000$1.17M$847,000
Free cash flow-$13.64M-$20.33M-$22.15M-$24.85M-$25.56M
Investing cash flow$17.74M$9.62M-$4.54M$13.27M-$20.57M
Financing cash flow-$6.60M$4.66M$18.15M$9.34M$30.28M
Depreciation & amortization$1.14M$1.38M$1.30M$1.51M$1.30M
Stock-based compensation$654,000$1.24M$1.11M$1.19M$2.61M

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.